icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
 
 
 
High Sustained Virologic Response Rates With Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions
 
 
  Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
 
Mark S. Sulkowski,1 Kris V. Kowdley,2 Leslie Bank,3 Julie Ma,4 Anita Mathias,4 John McNally,4 Diana M. Brainard,4 William T. Symonds,4
John G. McHutchison,4 Catherine Stedman,5 Kenneth E. Sherman,6 Raymond T. Chung7 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Virginia Mason Medical Center, Seattle, WA; 3Binghamton Gastroenterology Associates, New York, NY; 4Gilead Sciences Inc., Foster City, CA; 5Christchurch Clinical Studies Trust, Christchurch, New Zealand; 6University of Cincinnati College of Medicine, Cincinnati, OH; 7Massachusetts General Hospital, Boston, MA

hepDart1.gif

hepDart2.gif

hepDart3.gif

hepDart4.gif

hepDart5.gif

hepDart6.gif

hepDart7.gif

hepDart8.gif